Rifampin pharmacokinetics in children, with and without human immunodefiency virus infection, hospitalized for the management of severe forms of tuberculosis
: BMC Medicine OUTPUT TYPE
: Journal Article PUBLICATION YEAR
: H.S.Schaaf, M.Willemse, K.Cilliers, D.Labadarios, J.S.Maritz, G.D.Hussey, H.McIlleron, P.Smith, P.R.DonaldKEYWORDS
: ANTIRETROVIRAL THERAPY
, CHILD WELL-BEING
: HSRC Library: shelf number 5948
If you would like to obtain a copy of this Research Output, please contact Hanlie Baudin at email@example.com.
Rifampin is a key drug in antituberculosis chemotherapy because it rapidly kills the majority of bacilli in tuberculosis lesions, prevents relapse and thus enables 6-month short-course chemotherapy. Little is known about the pharmacokinetics of rifampin in children. The objective of this study was to evaluate the pharmacokinetics of rifampin in children with tuberculosis, both human immunodeficiency virus type-1-infected and human immunodeficiency virus-uninfected.
Fifty-four children, 21 human immunodeficiency virus-infected and 33 human immunodeficiency virus-uninfected, mean ages 3.73 and 4.05 years (P = 0.68), respectively, admitted to a tuberculosis hospital in Cape Town, South Africa with severe forms of tuberculosis were studied approximately 1 month and 4 months after commencing antituberculosis treatment. Blood specimens for analysis were drawn in the morning, 45 minutes, 1.5, 3.0, 4.0 and 6.0 hours after dosing. Rifampin concentrations were determined by liquid chromatography tandem mass spectrometry. For two sample comparisons of means, the Welch version of the t-test was used; associations between variables were examined by Pearson correlation and by multiple linear regression.
Both human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children with tuberculosis have very low rifampin serum concentrations after receiving standard rifampin dosages similar to those used in adults. Pharmacokinetic studies of higher dosages of rifampin are urgently needed in children to assist in placing the dosage of rifampin used in childhood on a more scientific foundation.
Related Research Outputs:
- Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa
- Children born into families affected by HIV
- Defining orphaned and vulnerable children
- An exploratory study of the impact of primary caregiver HIV infection on caregiving and child developmental outcome in the era of Haart: piloting the methodology
- A monitoring dilemma: orphans and children made vulnerable by HIV/AIDS
- Associations with HIV status in children with diarrhoea in Cape Town, South Africa
- Children's perspectives on death and dying in southern Africa in the context of the HIV/AIDS epidemic
- Impact of HIV/AIDS on children in South Africa: the case of orphans and vulnerable children
- Going to scale: a randomised community trial to determine the cost-effectiveness of alternative interventions to support highly vulnerable children and families in the context of HIV, AIDS and poverty
- We are volunteering: communities' responses to children in need
- Book review: Foster, G., Levi, C., and Williamson, J. (eds.) 2005. A generation at risk: the global impact of HIV/AIDS on orphans and vulnerable children. Cambridge: Cambridge University Press, ISBN 978-0-521-652643
- Editorial: strenghtening families for the care and protection of children affected by HIV and AIDS
- Improving hospital care for young children in the context of HIV/AIDS and poverty
- Strengthening families to support children affected by HIV and AIDS
- Community perceptions and understanding of the risk factors that affect children who are sexually abused
- Infants and young children affected by HIV/AIDS
- South African national HIV prevalence, incidence, behaviour and communication survey, 2008: the health of our children
- Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid
- Fragile families' experiences of caring for HIV-positive children: selected cases from the Eastern Cape and KwaZulu-Natal
- Making HIV testing services for children appropriate, accessible and available: key policy considerations